It is recognized that radiation therapy can eradicate microscopic tumor disease, even in postoperative prostate cancer patients, when extracapsular extension, positive surgical margins or increased prostate-specific antigen is found in surgical specimens. This review of recent literature analyzes and discusses acquired certainties and still open questions regarding type, timing, doses, techniques, toxicities, and associated hormonal therapies of radiotherapy prescribed after radical prostatectomy. Free full text available at www.tumorionline.it
HullG.W., RabbaniF., AbbasF., WheelerT.M., KattanM.W., ScardinoP.T.: Cancer control with radical prostatectomy alone in 1,000 consecutive patients.J Urol, 167: 528–534, 2002.
2.
BollaM., van PoppelH., ColletteL.: Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911).Lancet, 366: 572–578, 2005.
3.
JohnsonE.K., WoodD.P.Jr.: Converting from open to robotic prostatectomy: key concepts.Urol Oncol, 281: 77–80, 2010.
WiegelT., BottkeD., SteinerU., SiegmannA., GolzR., StörkelS., WillichN., SemjonowA., SouchonR., StöckleM., RübeC., WeissbachL., AlthausP., RebmannU., KälbleT., FeldmannH.J., WirthM., HinkeA., HinkelbeinW., MillerK.: Phase III results of adjuvant radiotherapy (RT) versus “wait and see” in patients with pT3 prostate cancer following radical prostatectomy (RP),(ARO 96-02/AUO AP 09/95).J Clin Oncol, 23: 4513, 2005.
6.
ThompsonI.A., TangenC.M., ParadeloJ., LuciaM.S., MillerG., TroyerD., MessingE., FormanJ., ChinJ., SwansonG., Canby-HaginoE., CrawfordE.D.: Adjuvant radiotherapy for pathological t3n0m0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow up of a randomized clinical trial.J Urol, 181: 956–962, 2009.
7.
SwansonP., ThompsonI.M.: Adjuvant radiotherapy for high-risk patients following radical prostatectomy.Urol Oncol, 25: 515–519, 2007.
8.
SwansonG.P., HusseyM.A., TangenC.M., ChinJ., MessingE., Canby-HaginoE., FormanJ.D., ThompsonI.M., CrawfordE.D.: Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794.J Clin Oncol, 25: 2225–2229, 2007.
9.
RoehlK.A., HanM., RamosC.G., AntenorJ.A., CatalonaW.J.: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results.J Urol, 172: 910–914, 2004.
10.
Van der KwastT.H., BollaM., Van PoppelH., Van CanghP., VekemansK., Da PozzoL., BossetJ.F., KurthK.H., SchröderF.H., ColletteL.: Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.J Clin Oncol, 25: 4178–4186, 2007.
11.
PasquierD., BallereauC.: Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review.Int J Radiat Oncol Biol Phys, 72: 972–979, 2008.
12.
Jereczek-FossaB.A., ZeriniD., VavassoriA., FodorC., SantoroL., MinissaleA., CambriaR., CattaniF., GaribaldiC., SerafiniF., MateiV.D., de CobelliO., OrecchiaR.: Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy.Int J Radiat Oncol Biol Phys, 74: 115–125, 2009.
13.
ChooR., HrubyG., HongJ., BahkE., HongE., DanjouxC., MortonG., DeBoerG.: (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy.Int J Radiat Oncol Biol Phys, 53: 269–276, 2002.
14.
StephensonA.J., ShariatS.F., ZelefskyM.J., KattanM.W., ButlerE.B., TehB.S., KleinE.A., KupelianP.A., RoehrbornC.G., PistenmaaD.A., PacholkeH.D., LiauwS.L., KatzM.S., LeibelS.A., ScardinoP.T., SlawinK.M.: Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.JAMA, 291: 1325–1332, 2004.
15.
MacdonaldO.K., SchildS.E., VoraS.A., AndrewsP.E., FerrigniR.G., NovickiD.E., SwansonS.K., WongW.W.: Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy.Int J Radiat Oncol Biol Phys, 58: 1530–1535, 2004.
16.
AmlingC.L., BergstralhE.J., BluteM.L., SlezakJ.M., ZinckeH.: Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?J Urol, 165: 1146–1151, 2001.
17.
FreedlandS.J., SutterM.E., DoreyF., AronsonW.J.: Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen.Urology, 61: 365–369, 2003.
18.
ScattoniV., MontorsiF., PicchioM., RoscignoM., SaloniaA., RigattiP., FazioF.: Diagnosis of local recurrence after radical prostatectomy.BJU Int, 93: 680–688, 2004.
19.
PelosiE., ArenaV., SkanjetiA., PirroV., DouroukasA., PupiA., ManciniM.: Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer.Radiol Med, 113: 895–904, 2008.
20.
GiovacchiniG., PicchioM., CoradeschiE., BettinardiV., GianolliL., ScattoniV., CozzariniC., Di MuzioN., RigattiP., FazioF., MessaC.: Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy.Eur J Nucl Med Mol Imaging, 37: 301–309, 2010.
21.
KoppieT.M., GrossfeldG.D., NudellD.M., WeinbergV.K., CarrollP.R.: Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy?J Urol, 166: 111–115, 2001.
22.
RoscignoM., CozzariniC., ScattoniV., BertiniR., Da PozzoL., PastaA., MontorsiF., BolognesiA., FiorinoC., ColomboR., FazioF., RigattiP.: A reappraisal of the role of vesicourethral anastomosis biopsy in patient candidates for salvage radiation therapy after radical prostatectomy.Radiother Oncol, 82: 30–37, 2007.
23.
AnscherM.S.: Salvage radiotherapy for recurrent prostate cancer: the earlier the better.JAMA, 291: 1380–1382, 2004.
24.
KubanD.A., TuckerS.L., DongL., StarkschallG., HuangE.H., CheungM.R., LeeA.K., PollackA.: Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer.Int J Radiat Oncol Biol Phys, 70: 67–74, 2008.
ValicentiR.K., GomellaL.G., IsmailM., MulhollandS.G., PetersenR.O., CornB.W.: Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer.Int J Radiat Oncol Biol Phys, 42: 501–506, 1998.
27.
ValicentiR.K., GomellaL.G., IsmailM., MulhollandS.G., StrupS., PetersenR.O., CornB.W., LuJ.D.: Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: the importance of radiation dose.Urology, 52: 1034–1040, 1998.
28.
CozzariniC., FiorinoC., MontorsiF., AlongiF., Da PozzoL.F., BolognesiA., Da PozzoL.F., GuazzoniG., FreschiM., RoscignoM., ScattoniV., RigattiP., Di MuzioN.: The need for high radiation doses (≥70 Gy) in early post-operative irradiation after radical prostatectomy. A mono institutional analysis on 334 consecutive high risk patients.Int J Radiat Oncol Biol Phys, 75: 966–974, 2009.
29.
KingC.R., KappD.S.: Radiotherapy after prostatectomy: is the evidence for dose escalation out there?Int J Radiat Oncol Biol Phys, 71: 346–350, 2008.
30.
ZelefskyM.J., AschkenasyE., KelsenS., LeibelS.A.: Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy.Int J Radiat Oncol Biol Phys, 39: 327–333, 1997.
31.
FiorinoC., AlongiF., BroggiS., CattaneoM., CozzariniC., Di MuzioN., MaggiulliE., MangiliP., PernaL., ValdagniR., FazioF., CalandrinoR.: Physics aspects of prostate tomotherapy: planning optimization and image-guided issues.Acta Oncol, 47: 1309–1316, 2008.
32.
AlongiF., FiorinoC., CozzariniC., BroggiS., PernaL., CattaneoG.M., CalandrinoR., Di MuzioN.: IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy.Radiother Oncol, 93: 207–212, 2009.
33.
PoortmansP., BossiA., VandeputteK., BossetM., MiralbellR., MaingonP., BoehmerD., BudihartoT., SymonZ., van den BerghA.C., ScraseC., Van PoppelH., BollaM., EORTC Radiation Oncology Group: Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group.Radiat Oncol, 84: 121–127, 2007.
34.
MichalskiJ.M., LawtonC., El NaqaI., RitterM., O'MearaE., SeiderM.J., LeeW.R., RosenthalS.A., PisanskyT., CattonC., ValicentiR.K., ZietmanA.L., BoschW.R., SandlerH., BuyyounouskiM.K., MénardC.: Development of RTOG Consensus Guidelines for the Definition of the Clinical Target Volume for Postoperative Conformal Radiation Therapy for Prostate Cancer.Int J Radiat Oncol Biol Phys, 76: 361–368, 2010.
35.
RoachM3rd, DeSilvioM., LawtonC., UhlV., MachtayM., SeiderM.J., RotmanM., JonesC., AsbellS.O., ValicentiR.K., HanS., ThomasC.R.Jr., ShipleyW.S., Radiation Therapy Oncology Group 9413: Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression.J Clin Oncol, 21: 1904–1911, 2003.
36.
HeidenreichA., VargaZ., Von KnoblochR.: Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.J Urol, 167: 1681–1686, 2002.
37.
CozzariniC., FiorinoC., Di MuzioN., AlongiF., BroggiS., CattaneoM., MontorsiF., RigattiP., CalandrinoR., FazioF.: Significant reduction of acute toxicity following pelvic irradiation with helical tomotherapy in patients with localized prostate cancer.Radiother Oncol, 84: 164–170, 2007.
38.
Da PozzoL.F., CozzariniC., BrigantiA., SuardiN., SaloniaA., BertiniR., GallinaA., BianchiM., FantiniG.V., BolognesiA., FazioF., MontorsiF., RigattiP.: Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.Eur Urol, 55: 1003–1011, 2009.
39.
BollaM., de ReijkeT.M., Van TienhovenG., Van den BerghA.C., OddensJ., PoortmansP.M., PoortmansP.M., GezE., KilP., AkdasA., SoeteG., KariakineO., van der Steen-BanasikE.M., MusatE., PiérartM., MauerM.E., ColletteL., EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group: Duration of androgen suppression in the treatment of prostate cancer.N Engl J Med, 360: 2516–2527, 2009.
40.
D'AmicoA.V., ManolaJ., LoffredoM., LoffredoM., RenshawA.A., Della CroceA., KantoffP.W.: 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial.JAMA, 292: 821–827, 2004.
41.
LeeA.K.: Radiation therapy combined with hormone therapy for prostate cancer.Semin Radiat Oncol, 16: 20–28, 2006.
42.
EulauS.M., TateD.J., StameyT.A., BagshawM.A., HancockS.L.: Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.Int J Radiat Oncol Biol Phys, 41: 735–740, 1998.
